Market Closed -
Other stock markets
|
After market 11:02:16 pm | |||
90 EUR | -0.53% | 90.6 | +0.66% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- The company is one of the best yield companies with high dividend expectations.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.29% | 123B | - | ||
+39.83% | 723B | C+ | ||
+34.28% | 595B | B | ||
-4.03% | 369B | C+ | ||
+20.42% | 332B | B- | ||
+2.97% | 282B | C+ | ||
+17.02% | 244B | B+ | ||
+9.31% | 208B | B- | ||
-5.07% | 205B | A+ | ||
-0.09% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SAN Stock
- SNW Stock
- Ratings Sanofi